272 related articles for article (PubMed ID: 29419653)
1. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.
Webster LR; Nalamachu S; Morlion B; Reddy J; Baba Y; Yamada T; Arjona Ferreira JC
Pain; 2018 May; 159(5):987-994. PubMed ID: 29419653
[TBL] [Abstract][Full Text] [Related]
2. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Webster LR; Yamada T; Arjona Ferreira JC
Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
[TBL] [Abstract][Full Text] [Related]
4. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
5. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
Wild J; Yamada T; Arjona Ferreira JC; Hale M
Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
[TBL] [Abstract][Full Text] [Related]
6. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
10. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD006332. PubMed ID: 36106667
[TBL] [Abstract][Full Text] [Related]
11. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
[TBL] [Abstract][Full Text] [Related]
13. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
Liu JJ; Quinton SE; Brenner DM
Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.
Webster LR; Michna E; Khan A; Israel RJ; Harper JR
Pain Med; 2017 Aug; 18(8):1496-1504. PubMed ID: 28810695
[TBL] [Abstract][Full Text] [Related]
16. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
Wobbe B; Gerner M; Köhne CH
BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
[TBL] [Abstract][Full Text] [Related]
17. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
[TBL] [Abstract][Full Text] [Related]
18. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
Webster L; Tummala R; Diva U; Lappalainen J
J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
[TBL] [Abstract][Full Text] [Related]
19. Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.
Murphy JA; Sheridan EA
Ann Pharmacother; 2018 Apr; 52(4):370-379. PubMed ID: 29092627
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
